All News

covid.corona

Vaccination Cut Long COVID Risk for Rheum Patients

d MedPage Today

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Read Article
Prgnancy,outcome

Pregnancy Outcomes with Belimumab

d Jack Cush, MD

Pregnancy in systemic lupus erythematosus (SLE) is fraught with problems of adverse pregnancy outcomes, more pregnancy loss and birth defects. Now a study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects.

Read Article
microbes.jpg

Prevotella Immune Response in Both Pre-Clinical & Established RA

d EurekAlert! and Jack Cush

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Read Article
Miner,coal,newcastle

Miners Face Increased Risk of Rheumatoid Arthritis

d MedPage Today

Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.

Read Article
oaknees.jpg

CRTAC1- a Novel Biomarker for Osteoarthritis

d EurekAlert!

Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.

Read Article

How do Pts check Temps? Paired oral & temporal temps in 2031 Blacks & 2344 Whites: / whites showed no diff (36.97 vs 36.95°C), but signif diff in blacks (36.98 vs 37.05). Fever seen in 10.2-10.8% Whites, but 10.1% (temporal), 13.2% (oral) in Blacks https://t.co/D4XowfsYXD https://t.co/LmvEnAVGbr

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/cXm58iSmVc https://t.co/Hdg6Qg1uHE

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevotella Immune Response in Both Pre-Clinical & Established RA In a recent analysis published in Arthritis & Rheumatology, people at risk for RA and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). https://t.co/6zArTx4XlM https://t.co/9UIk2OOhXq

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS

Links:

Dr. John Cush RheumNow ( View Tweet)
mRNA COVID vaccine study from Vaccine Safety Datalink shows risk of myocarditis/pericarditis 0-7d post Vax (ages 5-39) is ~1/200K doses (1st dose), 1/ 30K(2nd dose), 1/50K (1st booster); w/ higher risk in adolescent males https://t.co/J1u038qxB7 https://t.co/vEUNbOvEQf

Links:

Dr. John Cush RheumNow ( View Tweet)

Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/rcnTPkDTjq https://t.co/RbW1fPSjfU

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/UeIZ70zRnt https://t.co/tGrBSydvKB

Links:

Dr. John Cush RheumNow ( View Tweet)
Top Tweet of September: Gout: diagnosis and management—summary of NICE guidance https://t.co/CWg4otNBVv https://t.co/wRcjnC59eL

Links:

Dr. John Cush RheumNow ( View Tweet)
Long COVID study (54 studies, 2 databases, 1.2 million pts) showed at least 1 in 3 reported Long COVID Sx clusters (fatigue, bodily pain, mood swings, cognitive or resp Sxs), more common in women <20 yrs, w/ duration 9 mos in Hosp pts https://t.co/vuJrpWizzr https://t.co/e58J8rctEC

Links:

Dr. John Cush RheumNow ( View Tweet)
Spinal cord stimulation is a $2-3billion market, despite limited efficacy. A placebo controlled trial of spinal cord burst stimulation, in 50 pts w/ chr radicular pain after lumbar surgery, showed no significant benefit in back pain–related disability. https://t.co/aRN5sRbqFx https://t.co/A37LWaYEGw

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Kent Kwoh and Researchers at the University of Arizona Arthritis Center have been awarded a $3.4 million grant from the National Institutes of Health to undertake a study that seeks to identify determinants of rapid knee deterioration in OA https://t.co/EodUXk6FDp https://t.co/bX2k5c7lR9

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM: Dysphagia Due to Diffuse Idiopathic Skeletal Hyperostosis - 70yoM with 6-month history of dysphagia. Compression of the hypopharyx by large cervical osteophytes was seen in a videofluoroscopic swallowing study https://t.co/AVDXPzhfjd https://t.co/7TwY0CGaxb

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 291 PCPs shows that increased electronic health record (EHR) time was associated with a significantly greater liklihood of meeting patient target goals for Hgb-A1C, HTN control and breast cancer screening https://t.co/mLdoHM9N7O https://t.co/li6QD5jq7F

Links:

Dr. John Cush RheumNow ( View Tweet)
Arthritis Clinical Trials Comparison Grid Use this resource to keep track of your clinical trials and key information needed when communicating with patients about a drug study. https://t.co/9z42zfr1Fx https://t.co/dYAjOVvTaW

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/38xOWb1zJi https://t.co/jPUy6H1QQN

Links:

Dr. John Cush RheumNow ( View Tweet)
×